Clinical Trial

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Name: Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy — clinical trial record (NCT07426484)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-12

Trial Details

NCT Number	NCT07426484
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Checkpoint Therapeutics, Inc.
Conditions	Cutaneous Squamous Cell Carcinoma, Skin Cancer
Enrollment	80 participants
Start Date	2026-04-23
Primary Completion	2030-12-15 (estimated)
Study Completion	2032-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-11